# Breathe — Healthcare Investment Intelligence

> diagnostics. MedFuel Intel profile as of 2026-06-12.

Breathe BioMedical is developing a breath analytics platform technology to detect early-stage breast cancer in women with dense breast tissue as an adjunct to mammography, achieving 88.2% accuracy in identifying breath signature differences.[1][2][3] The company launched a multi-center clinical trial in February 2025 at George Washington University Breast Center and combines breath sampling, infrared spectroscopy, and machine learning for non-invasive disease detection.[3][6]

## Key facts (as of 2026-06-12)
- Sector: diagnostics
- Website: https://breathebiomedical.com/

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/breathe. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.